Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET.

Department of Bioengineering and Therapeutic Sciences, and California Institute for Quantitative Biosciences, University of California, San Francisco, CA 94158, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 09/2011; 108(38):15810-5. DOI: 10.1073/pnas.1106030108
Source: PubMed

ABSTRACT The norepinephrine transporter (NET) transports norepinephrine from the synapse into presynaptic neurons, where norepinephrine regulates signaling pathways associated with cardiovascular effects and behavioral traits via binding to various receptors (e.g., β2-adrenergic receptor). NET is a known target for a variety of prescription drugs, including antidepressants and psychostimulants, and may mediate off-target effects of other prescription drugs. Here, we identify prescription drugs that bind NET, using virtual ligand screening followed by experimental validation of predicted ligands. We began by constructing a comparative structural model of NET based on its alignment to the atomic structure of a prokaryotic NET homolog, the leucine transporter LeuT. The modeled binding site was validated by confirming that known NET ligands can be docked favorably compared to nonbinding molecules. We then computationally screened 6,436 drugs from the Kyoto Encyclopedia of Genes and Genomes (KEGG DRUG) against the NET model. Ten of the 18 high-scoring drugs tested experimentally were found to be NET inhibitors; five of these were chemically novel ligands of NET. These results may rationalize the efficacy of several sympathetic (tuaminoheptane) and antidepressant (tranylcypromine) drugs, as well as side effects of diabetes (phenformin) and Alzheimer's (talsaclidine) drugs. The observations highlight the utility of virtual screening against a comparative model, even when the target shares less than 30% sequence identity with its template structure and no known ligands in the primary binding site.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Genome-Wide Association Studies (GWAS), whole genome sequencing, and high-throughput omics techniques have generated vast amounts of genotypic and molecular phenotypic data. However, these data have not yet been fully explored to improve the effectiveness and efficiency of drug discovery, which continues along a one-drug-one-target-one-disease paradigm. As a partial consequence, both the cost to launch a new drug and the attrition rate are increasing. Systems pharmacology and pharmacogenomics are emerging to exploit the available data and potentially reverse this trend, but, as we argue here, more is needed. To understand the impact of genetic, epigenetic, and environmental factors on drug action, we must study the structural energetics and dynamics of molecular interactions in the context of the whole human genome and interactome. Such an approach requires an integrative modeling framework for drug action that leverages advances in data-driven statistical modeling and mechanism-based multiscale modeling and transforms heterogeneous data from GWAS, high-throughput sequencing, structural genomics, functional genomics, and chemical genomics into unified knowledge. This is not a small task, but, as reviewed here, progress is being made towards the final goal of personalized medicines for the treatment of complex diseases.
    PLoS Computational Biology 05/2014; 10(5):e1003554. · 4.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aflatoxin, a naturally occurring mycotoxin, produced by Aspergillus parasiticus infects peanuts and many other legumes. Among 23 enzymatic reactions involved in aflatoxin biosynthesis, only 15 are identified so far. Versicolorin B synthase (vbs) is the key enzyme involved in aflatoxin biosynthesis. It converts hydroxy versiconal acetate (VHA) to versicolorin B (VERB), which is finally converted into aflatoxin in a series of reactions. We selected two naturally available compounds, allicin and ajoene present in onion and garlic, to analyse their inhibitory effect on aflatoxin biosynthesis. Additionally, we virtually derived a new compound called ajocin (allicin + ajoene) to study their synergistic effect in preventing aflatoxin biosynthesis. We aim to compare the inhibitory action of these compounds against 15 known enzyme targets through docking simulations using Autodock. The best inhibitory action is reported by ajocin against the key enzyme, vbs. In silico docking studies thus confirm the enhanced inhibitory property of ajocin and reduce the risk of aflatoxin (carcinogen) exposure to human.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Discovery of new inhibitors of the plasmalemmal monoamine transporters (MATs) continues to provide pharmacotherapeutic options for depression, addiction, attention deficit disorders, psychosis, narcolepsy and Parkinson's disease. The recent windfall of high-resolution MAT structural information afforded by x-ray crystallography has enabled the use of in silico methods in MAT drug discovery. Here, virtual screening (VS) of the PubChem small molecule structural database using the S1 (primary substrate) ligand pocket of a serotonin transporter computational homology model yielded 19 prominent "hit" compounds. In vitro pharmacology of these VS hits revealed four structurally unique MAT substrate uptake inhibitors with high nanomolar affinity at one or more of the three MATs. In vivo characterization of three of these hits revealed significant activity in a mouse model of acute depression, at doses that did not elicit untoward locomotor effects. This constitutes the first report of MAT inhibitor discovery using the primary substrate pocket as a VS tool. Novel-scaffold MAT inhibitors offer hope of new medications that lack the many classic adverse effects of existing antidepressant drugs.
    ACS Chemical Neuroscience 07/2014; · 4.21 Impact Factor

Full-text (2 Sources)

Available from
May 29, 2014